Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

Major Depressive Disorder Clinical Trial

Official title:

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01312922
• Other study ID #: PNB01-C301
• Secondary ID: 2011-001190-11
• Status: Completed
• Phase: Phase 3
• Start date: September 2011
• Est. completion date: December 2012

Study information

• Verified date: March 2022
• Source: PharmaNeuroBoost N.V.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall objective of this trial is to demonstrate clinically relevant superior antidepressant efficacy of the fixed dose combination PNB01 (low dose pipamperone and citalopram) over reference antidepressant treatment with citalopram alone, and a low dose of psychoactive pipamperone alone in patients with moderate to severe Major Depressive Disorder. This study was specifically designed to assess patient related outcome (PRO) parameters using an Interactive Voice Response System (IVRS) via telephone.

Description:

This is an international, double-blind, centrally randomized (stratified), multicenter study in 555 patients suffering from moderate to severe MDD in up to 40 sites in the USA, Germany and Canada. Eligible out-patients will be treated once daily (QD) with a fixed dose of either PNB01 (PIP 15 mg / CIT 20 mg (Week 1) - PIP 15 mg / CIT 40 mg (Week 2-10)), CIT alone (CIT 20 mg (Week 1) - CIT 40 mg (Week 2-10) or PIP 15 mg alone (Week 1-10) in a 1:1:1 ratio in a double-blind fashion for 10 weeks. Study visits will be conducted 1, 2, 3, 4, 6, 8 and 10 weeks after study treatment initiation. Possible withdrawal effects will be assessed 1 week after study treatment withdrawal. A blood sample for pharmacokinetic analysis will be collected when drawing blood for routine biochemistry. Patients who provided written informed consent to participate to the study will be asked to provide their consent to participate also to the non-mandatory pharmacogenetic study. Patient related outcomes will be collected electronically (ePRO) at study visits prior to visiting the investigator by using an Interactive Voice Response System (IVRS) via telephone. Patients wishing or choosing to discontinue the study treatment prematurely will be encouraged to continue to provide their scores, safety data and medications taken, up to the scheduled study end, by telephone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 555
• Est. completion date: December 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.

2. Patient understands the investigational nature of the trial and is willing and able to comply with the trial requirements.

3. Patient is male or female, aged = 18 years.

4. Patient has MDD according to the DSM IV-R criteria with an existence of depressed mood (DSM-IV-R Crit. A1) and loss of interest/anhedonia (DSM-IV-R Crit. A2) as confirmed by the MINI, lasting for at least 4 weeks and no longer than 18 months (78 weeks) for the current episode, and causing significant functional impairment (DSM-IV-R MDD C- criterion).

5. CGI-S rating of at least 4 and a minimum MADRS total score of 26 using IVRS ePRO at Baseline.

Exclusion Criteria:

1. Patient is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or who does not consistently use 2 combined effective methods of contraception (including at least 1 barrier method), unless sexually abstinent.

2. Existence of Mood Disorder with psychotic features and/or high suicidality risk, as confirmed by MINI.

3. Concomitant diagnosis of any additional primary Axis I disorder and presence of any of the following co-morbid disorders: (Hypo)manic episode, Panic Disorder (limited symptom attacks allowed), Obsessive Compulsive Disorder, Post-traumatic Stress Disorder, Alcohol dependence, any other Substance abuse and/or dependence, Psychotic Disorder, Eating Disorder, or General Anxiety Disorder, as confirmed by MINI.

4. Concomitant diagnosis of any primary Axis II disorder.

5. Patient is hospitalized.

6. Patient has a clinically relevant renal dysfunction (e.g. GFR <60mL/min).

7. Patient has hepatic dysfunction (total bilirubin >2.0mg/dL or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than 2 times the upper limit of the reference range).

8. Patient has a malignant neoplastic disease, a documented history of epilepsy (juvenile convulsions excepted) or a documented, in the opinion of the investigator, clinically relevant risk of bleeding (eg. severe bleeding disorder, treatment with warfarin, …).

9. Patient with a documented history or concomitant diagnosis or significant risk of cardiac arrhythmia or dysrhythmia, including a QTc interval of =500 ms at Baseline.

10. Patient has any other medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the patient's ability to participate in this trial or that would interfere with trial assessments.

11. Patient with documented alcohol or drug abuse, or having a positive standard screen for alcohol or drugs (including benzodiazepines and opioids).

12. Patient received, in the past 7 days treatment with any psychoactive drug prior to randomization, including typical and atypical antipsychotics, hypnotics, antidepressants, anxiolytic drugs, anticonvulsive therapy, opioids, monoamine oxidase (MAO) inhibitors, sedative antihistamines, psychostimulants or amphetamines, dopamine D2 receptor antagonists, butyrophenones, metoclopramide, lithium, anticonvulsants, benzodiazepines, or barbiturates. If patient has received such therapy, a washout period of at least 7 days prior to baseline is required before inclusion in this trial (except fluoxetine: 4 weeks, and St John's Wort or MAO inhibitors: within 2 weeks).

13. Concomitant treatment with diuretics, QT prolongation drugs, or dopamine agonists.

14. Resistant depression defined as having failed to respond to either: a/ 2 previous antidepressants at an adequate dose administered for at least 4 weeks during the current episode; b/ augmentation therapy with any atypical antipsychotic drug

15. Electroconvulsive therapy (ECT) or repetitive Transcranial Magnetic Stimulation therapy (rTMS) within the last 6 months; Vagus Nerve Stimulation (VNS) or Deep Brain Stimulation (DBS) ever.

16. Formal psychotherapy or alternative treatment for 1 week prior to or during the study.

17. Patient has participated in another trial of an investigational agent (including medical device) within the last 3 months prior to baseline or is currently participating in another trial of an investigational drug.

18. Known hypersensitivity to any of the study drugs

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• PNB01 fixed dose combination of pipamperone and citalopram
oral once daily administration
• Citalopram
oral once daily administration
• Pipamperone
oral once daily administration

Locations

Country	Name	City	State
Canada	Site 205	Chatham	Ontario
Canada	Site 201	Kelowna	British Columbia
Canada	Site 203	Mississauga	Ontario
Canada	Site 204	Mississauga	Ontario
Canada	Site 202	Penticton	British Columbia
United States	Site 105	Allentown	Pennsylvania
United States	Site 133	Atlanta	Georgia
United States	Site 119	Austin	Texas
United States	Site 110	Baltimore	Maryland
United States	Site 126	Beachwood	Ohio
United States	Site 127	Cincinnati	Ohio
United States	Site 104	Dallas	Texas
United States	Site 109	Flowood	Mississippi
United States	Site 112	Fort Myers	Florida
United States	Site 103	Glendale	California
United States	Site 107	Kirkland	Washington
United States	Site 132	Libertyville	Illinois
United States	Site 123	Media	Pennsylvania
United States	Site 135	Miami	Florida
United States	Site 124	Middleburg Heights	Ohio
United States	Site 101	National City	California
United States	Site 115	New York	New York
United States	Site 122	Philadelphia	Pennsylvania
United States	Site 113	Riverside	California
United States	Site 106	San Diego	California
United States	Site 116	San Diego	California
United States	Site 117	Schaumburg	Illinois
United States	Site 134	Seattle	Washington
United States	Site 128	Smyrna	Georgia
United States	Site 102	Wichita Falls	Texas
United States	Site 108	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
PharmaNeuroBoost N.V.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Early and Sustained (Antidepressant) Response (ESR) Rate	Early and Sustained Response (ESR) is defined as a MADRS total score reduction from Baseline of 50% or more and a MADRS total score =16 at Week 2, Week 3, Week 4, and Week 6.	From (end of) Week 2 visit to (end of) Week 6 visit
Secondary	Change From Baseline in Total MADRS Score at Week 6	Change from baseline in total score on the Montgomery-Asberg Depression Rating Scale (MADRS) after 6 weeks of study treatment as assessed by the patient using an Interactive Voice Response System (IVRS) via telephone; The MADRS scale is a widely used and well-validated 10-item diagnostic questionnaire designed to measure the severity of depressive episodes in patients with mood disorders. The 10 items are all rated on a scale from 0 to 6 (resulting in a maximum total score of 60 points) and include 'apparent sadness', 'reported sadness', 'inner tension', 'reduced sleep', 'reduced appetite', 'concentration difficulties', 'lassitude', 'inability to feel', 'pessimistic thoughts' and 'suicidal thoughts'. Higher scores indicative of greater depressive symptomology.	From Baseline (Day 1) to (end of) Week 6
Secondary	Change From Baseline in Total SDS Score at Week 6	Change from baseline in total score on the Sheehan Disability Scale (SDS) after 6 weeks of study treatment as assessed by the patient using an Interactive Voice Response System (IVRS) via telephone; The SDS is a generic brief self-report tool that was developed to assess functional impairment in three inter-related domains; 1) work or school, 2) social life and 3) family life. The patient rates the extent to which work/school, social life and home life or family responsibilities are impaired by his or her symptoms on a 10-point visual analog scale. Total scores range from a minimum of 0 to a maximum of 30 (0 unimpaired, 30 highly impaired).	From Baseline (Day 1) to (end of) Week 6 visit